Merck & Co. Files 8-K on Shareholder Votes and Notes

Ticker: MRK · Form: 8-K · Filed: 2024-05-30T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, debt-issuance, filing

TL;DR

Merck filed an 8-K covering shareholder votes and debt maturities.

AI Summary

On May 28, 2024, Merck & Co., Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and other events. The filing includes financial statements and exhibits, with specific references to various note issuances due in 2024, 2026, 2034, and 2036.

Why It Matters

This filing provides transparency on corporate actions and financial instruments, which is crucial for investors to assess the company's financial health and governance.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of corporate events and financial information, not indicating any immediate operational or financial distress.

Key Numbers

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the excerpt.

What are the different types of notes issued by Merck & Co., Inc. mentioned in the filing?

The filing mentions A.500 Notes due 2024, A1.875 Notes due 2026, A2.500 Notes due 2034, and A1.375 Notes due 2036.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is May 28, 2024.

What is the state of incorporation for Merck & Co., Inc.?

Merck & Co., Inc. is incorporated in New Jersey.

What is the Commission File Number for Merck & Co., Inc.?

The Commission File Number for Merck & Co., Inc. is 001-06571.

From the Filing

0001628280-24-025800.txt : 20240530 0001628280-24-025800.hdr.sgml : 20240530 20240530161421 ACCESSION NUMBER: 0001628280-24-025800 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 22 CONFORMED PERIOD OF REPORT: 20240528 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240530 DATE AS OF CHANGE: 20240530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 241005555 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 8-K 1 mrk-20240528.htm 8-K mrk-20240528 0000310158 False 0000310158 2024-05-28 2024-05-28 0000310158 us-gaap:CommonStockMember 2024-05-28 2024-05-28 0000310158 mrk:A.500NotesDue2024Member 2024-05-28 2024-05-28 0000310158 mrk:A1.875NotesDue2026Member 2024-05-28 2024-05-28 0000310158 mrk:A2.500NotesDue2034Member 2024-05-28 2024-05-28 0000310158 mrk:A1.375NotesDue2036Member 2024-05-28 2024-05-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Merck & Co., Inc. (Exact name of registrant as specified in its charter) New Jersey 1-6571 22-1918501 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 126 East Lincoln Avenue , Rahway , NJ 07065 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code): ( 908 ) 740-4000 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock ($0.50 par value) MRK New York Stock Exchange 0.500% Notes due 2024 MRK 24 New York Stock Exchange 1.875% Notes due 2026 MRK/26 New York Stock Exchange 2.500% Notes due 2034 MRK/34 New York Stock Exchange 1.375% Notes due 2036 MRK 36A New York Stock Exchange Item 5.07. Submission of Matters to a Vote of Security Holders. (a) The Annual Meeting of Shareholders of Merck & Co., Inc. (the “Company”) was held on May 28, 2024. (b) Shareholde

View on Read The Filing